Sophrosyne logo

Our Team

Sophrosyne is Led by Top-tier Executives with Clear Focus & Passion on Execution and Building Enterprise Value
  • Herm Cukier Chief Executive Officer headshot

    Herm Cukier

    Chief Executive Officer

  • Randall Marshall, M.D. Chief Medical Officer headshot

    Randall Marshall, M.D.

    Chief Medical Officer

  • Adam Sabouni, PhD Chief Development Officer headshot

    Adam Sabouni, PhD

    Chief Development Officer

  • Thomas Bailey, PhD Chemistry Lead headshot

    Thomas Bailey, PhD

    Chemistry Lead

  • Shawn Knopp, PhD CMC Lead headshot

    Shawn Knopp, PhD

    CMC Lead

  • Andrew Fowlie, PhD Head of Toxicology headshot

    Andrew Fowlie, PhD

    Head of Toxicology

  • Neil Chapman Chief of Staff headshot

    Neil Chapman

    Chief of Staff

Board of Directors

  • Don Wilson CEO of DRW headshot

    Don Wilson

    CEO of DRW

  • David Nelson President at DRW headshot

    David Nelson

    President at DRW

  • Lewis Feldberg Founder and Chairman of Sophrosyne headshot

    Lewis Feldberg

    Founder and Chairman of Sophrosyne

  • Herm Cukier Chief Executive Officer headshot

    Herm Cukier

    Chief Executive Officer

Advisory Board

  • Raymond F. Anton, M.D.

    Addiction Psychiatrist and Clinical Neuroscientist

  • Kelly J. Clark, MD, MBA

    Psychiatrist, Addiction Physician, Business Leader

  • Dr. Michelle Lofwall

    Professor in the Departments of Behavioral Science and Psychiatry and the Bell Alcohol and Addictions Endowed Chair

Today’s standard of care is woefully antiquated and inadequate, with more than 90% of patients relapsing after treatment. Sophrosyne’s novel compounds hold the promise of fundamentally transforming the treatment experience for the roughly 30 million patients of AUD in the U.S. and hundreds of millions more around the world.
Herm CukierCEO, Sophrosyne Pharmaceuticals